Last update:

Clinical pharmacology news

At 'most favored nation' prices, can Medicare break even on GLP-1 drugs?

In November 2025, the White House announced pricing deals with multiple pharmaceutical manufacturers to lower domestic prices for glucagon-like peptide-1 receptor agonist drugs (GLP-1RAs) including Ozempic, Wegovy, Mounjaro, ...

Statistical method may overstate Alzheimer's drugs' cognitive benefits by 29 times

A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown University School of Public Health.

New drug target identified for Fragile X syndrome

UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly one in 2,000 boys.

Viagra could hold key to halting Peyronie's disease

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

That discount at the pharmacy counter may pack hidden costs

Next time you go to the pharmacy, you might be offered a coupon on your prescription drugs. While it may sound like a great deal—with the prospect of saving hundreds of dollars—the decision to accept it is complicated, especially ...

Metformin's real power may be in the gut

For decades, physicians and scientists thought metformin, the leading type 2 diabetes medication taken by millions worldwide, mainly targets the liver to suppress glucose production. But a new Northwestern University study ...

Technology receives FDA approval for breast cancer treatment

More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer ...

Lithium uncovers fresh Alzheimer's targets beyond Tau

Lithium chloride may affect many cellular level changes in Alzheimer's disease, a new study from the University of Eastern Finland (UEF) shows. The work is published in the journal Biomedicine & Pharmacotherapy.